These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6615691)

  • 1. Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis.
    Dew MJ; Ryder RE; Evans N; Evans BK; Rhodes J
    Br J Clin Pharmacol; 1983 Aug; 16(2):185-7. PubMed ID: 6615691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis.
    Dew MJ; Ebden P; Kidwai NS; Lee G; Evans BK; Rhodes J
    Br J Clin Pharmacol; 1984 Apr; 17(4):474-6. PubMed ID: 6144318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease.
    Hardy JG; Healey JN; Reynolds JR
    Aliment Pharmacol Ther; 1987 Aug; 1(4):273-80. PubMed ID: 2979672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An oral preparation to release drugs in the human colon.
    Dew MJ; Hughes PJ; Lee MG; Evans BK; Rhodes J
    Br J Clin Pharmacol; 1982 Sep; 14(3):405-8. PubMed ID: 7126413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis.
    Mardini HA; Lindsay DC; Deighton CM; Record CO
    Gut; 1987 Sep; 28(9):1084-9. PubMed ID: 3678967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid.
    Dew MJ; Hughes P; Harries AD; Williams G; Evans BK; Rhodes J
    Br Med J (Clin Res Ed); 1982 Oct; 285(6347):1012. PubMed ID: 6127137
    [No Abstract]   [Full Text] [Related]  

  • 7. 5-Aminosalicylic acid in patients with ulcerative colitis in remission: plasma levels after administration of a new rectal enema.
    Gionchetti P; Belluzzi A; Campieri M; Torresan F; Tabanelli GM; Brignola C; Miglioli M; Barbara L
    Methods Find Exp Clin Pharmacol; 1988 Oct; 10(10):667-9. PubMed ID: 3236941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state pharmacokinetics of enteric coated 5-amino-salicylic acid tablets in healthy volunteers and in patients with Crohn's disease or ulcerative colitis.
    Norlander B; Gotthard R; Ström M
    Aliment Pharmacol Ther; 1991 Jun; 5(3):291-300. PubMed ID: 1888828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraluminal colonic release of immunoreactive tumour necrosis factor in chronic ulcerative colitis.
    Casellas F; Papo M; Guarner F; Antolín M; Armengol JR; Malagelada JR
    Clin Sci (Lond); 1994 Oct; 87(4):453-8. PubMed ID: 7834999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oroileal transit of slow release 5-aminosalicylic acid.
    Goebell H; Klotz U; Nehlsen B; Layer P
    Gut; 1993 May; 34(5):669-75. PubMed ID: 8504969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
    Rachmilewitz D
    BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.
    Staerk Laursen L; Stokholm M; Bukhave K; Rask-Madsen J; Lauritsen K
    Gut; 1990 Nov; 31(11):1271-6. PubMed ID: 2253912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and evaluation of colon adhesive pellets of 5-aminosalicylic acid.
    Xu M; Sun M; Qiao H; Ping Q; Elamin ES
    Int J Pharm; 2014 Jul; 468(1-2):165-71. PubMed ID: 24746693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antioxidant properties of 5-aminosalicylic acid: potential mechanism for its protective effect in ulcerative colitis.
    Miles AM; Grisham MB
    Adv Exp Med Biol; 1995; 371B():1317-21. PubMed ID: 7502808
    [No Abstract]   [Full Text] [Related]  

  • 15. Mesalazine release from coated tablets: effect of dietary fibre.
    Riley SA; Tavares IA; Bishai PM; Bennett A; Mani V
    Br J Clin Pharmacol; 1991 Aug; 32(2):248-50. PubMed ID: 1657094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negligible excretion of 5-aminosalicylic acid in breast milk.
    Klotz U; Harings-Kaim A
    Lancet; 1993 Sep; 342(8871):618-9. PubMed ID: 8102746
    [No Abstract]   [Full Text] [Related]  

  • 17. Scintigraphic study of gastrointestinal transit and disintegration sites of mesalazine tablets labeled with technetium-99m.
    Sciarretta G; Furno A; Mazzoni M; Ferrieri A; Malaguti P
    Scand J Gastroenterol; 1993 Sep; 28(9):783-5. PubMed ID: 8235433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion.
    Campieri M; Lanfranchi GA; Boschi S; Brignola C; Bazzocchi G; Gionchetti P; Minguzzi MR; Belluzzi A; Labò G
    Gut; 1985 Apr; 26(4):400-5. PubMed ID: 3979912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
    Schroeder KW; Tremaine WJ; Ilstrup DM
    N Engl J Med; 1987 Dec; 317(26):1625-9. PubMed ID: 3317057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis.
    Casellas F; Papo M; Guarner F; Antolín M; Segura RM; Armengol JR; Malagelada JR
    Eur J Gastroenterol Hepatol; 1995 Mar; 7(3):221-6. PubMed ID: 7743303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.